Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
Revvity to Present at Upcoming Investor Conferences
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Barclays PLC from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Revvity, Inc. (NYSE: RVTY) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $145.00 price target on the stock, up previously from $140.00.